<DOC>
	<DOCNO>NCT02688088</DOCNO>
	<brief_summary>This study know `` drug interaction study '' do see abemaciclib may affect blood level drug mixture commonly use drug ( caffeine , warfarin , dextromethorphan , midazolam ) take combination abemaciclib . Each participant complete screen four study period , option continue receive abemaciclib safety extension phase . All participant complete safety follow-up .</brief_summary>
	<brief_title>A Study Abemaciclib Participants With Cancer That Advanced Has Spread Another Part ( ) Body</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Have histological cytological evidence diagnosis cancer advance and/or metastatic Have adequate organ function Have performance status â‰¤2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous therapy cancer ( include chemotherapy , radiotherapy , immunotherapy , cancerrelated hormonetherapy , investigational therapy ) least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive study drug recover acute effect therapy ( treatment relate toxicity resolve baseline ) , except residual alopecia Require treatment inducer inhibitor cytochrome P450 ( CYP ) 1A2 , CYP2C9 , CYP2D6 , CYP3A within 14 day first dose study drug end Period 2 History presence significant bleeding disorder Have know active uncontrolled symptomatic CNS metastasis Have primary liver tumor Have lymphoma leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>